NEW YORK (GenomeWeb) – Patient advocates publicly urged the US Food and Drug Administration this week to quickly approve an investigational therapy for children suffering from a kind of brain cancer with a dire prognosis that has shown promising efficacy and a far better safety profile than the current options of radiation and chemotherapy.
Patients, Advocates Urge FDA to Expedite Approval of ONC201 for Rare, Mutation-Defined Gliomas
Premium
Get the full story with
Premium Access
Only $95 for the
first 90 days*
Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.